This document is a patent application (US20260083698A1) filed with the USPTO on September 19, 2023. It describes a novel therapeutic method for treating muco-obstructive disorders, specifically cystic fibrosis, by administering a combination of a b-adrenergic agonist or adenylate cyclase activator and a cholinergic agonist. The application details the synergistic stimulation of mucociliary clearance as the mechanism of action.

While patent applications are not regulations, they indicate potential future developments in pharmaceutical treatments. Companies involved in drug development for respiratory diseases, particularly cystic fibrosis, should be aware of this patented technology. Compliance officers in the pharmaceutical sector should monitor the progression of this patent and similar research, as it may influence future product development and regulatory submissions in the area of muco-obstructive disorder treatments.